OPTHF - Two Top Biotechs Forge MDMA Supply Deals For Clinical Research | Benzinga
Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA’s potential effects on addiction treatment.
PharmAla Signs Sale Agreement With Numinus
PharmAla Biotech Holdings, a biotech company researching, developing and manufacturing proprietary MDMA "LaNeo" and new MDMA derivatives (aka MDXX-class molecules) entered into a binding sales agreement with Numinus Wellness to provide its GMP MDMA LaNeo for a prospective clinical trial, now holding for approval.
PharmAla's CEO and founder Nick Kadysh says the company is looking forward to supporting their new partners in their efforts, adding that LaNeo "is undoubtedly the drug product of choice for MDMA clinical trial practitioners in Canada and around the world" and "increasingly, for prescribers as well."
The research to be performed by Numinus aims to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants. The trial would allow Numinus to study MDMA-assisted psychotherapy with groups and "better understand the optimum number of therapists required to deliver the programs safely," as well as provide eligible trainees with the opportunity to build core competencies and legally experience MDMA.
Join us for the latest cannabis deals at ...